Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent Diabetes is Now Available in Germany
Dexcom's Life-Changing Mobile CGM Technology for Diabetes Management Now a Covered Benefit for Patients with Diabetes in Germany
SAN DIEGO and EDINBURGH, Scotland, Sept. 7, 2016 /PRNewswire/ -- Dexcom, Inc., (NASDAQ:DXCM), announced that Germany's Federal Joint Committee (G-BA) will provide reimbursement for Dexcom's Continuous Glucose Monitoring (CGM) Systems for patients with insulin-dependent type 1 and type 2 diabetes. The policy change was approved by Germany's Ministry of Health and has now been initiated. This decision by the G-BA will open the door for many patients to benefit from the advanced CGM technology and help them gain better control of their diabetes. The new reimbursement policy in Germany only covers technologies that provide alarms and alerts about glucose levels – including the Dexcom CGM System. "We are thrilled that Dexcom CGM Systems are now accessible and affordable to patients throughout Germany," said Kevin Sayer, President and Chief Executive Officer of Dexcom. "This ground-breaking technology plays a vital role for people with diabetes who are insulin-dependent, allowing them to self-monitor their condition, manage their glucose levels and reduce risk of severe hyper or hypoglycemic events." The Dexcom G5® Mobile CGM System and Dexcom G4® PLATINUM will be included among the CGM devices that will be reimbursed by Germany's Medical Department of the Central Federal Association of Health Insurance Funds. With 288 glucose readings per day, patients using the Dexcom G5 Mobile CGM System can see their glucose levels and make treatment decisions based on the speed and direction of their readings.1 It also gives patients the added convenience of seeing their readings directly on their mobile device.2 G5 Mobile allows patients to share their glucose readings with up to five friends and family, which provides an additional layer of support for patients. "This is a major win for patients with diabetes in Germany," said Rudolf Messer, MD, Country Manager, Germany. "Before the new ruling took effect, Germany's strict reimbursement policies prevented many people with diabetes from benefitting from CGM, so only a small subset of the insulin-dependent diabetic population in Germany had access to this important and potentially life-saving technology. Now countless people with diabetes, along with their family members and loved ones, will have access to innovative, quality tools to help manage their condition." Germany is the single largest market in Europe for type 1 and type 2 diabetes, with nearly 6.6 million people living with the disease, according to the International Diabetes Federation.3 About Dexcom, Inc. *dQ&A patient surveys, 2009-2016 Cautionary Statement Regarding Forward Looking Statements MEDIA CONTACT: INVESTOR CONTACT: References
Logo - http://photos.prnewswire.com/prnh/20150811/257482LOGO To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/reimbursement-of-dexcom-cgm-technology-for-patients-with-type-1-and-type-2-insulin-dependent-diabetes-is-now-available-in-germany-300324182.html SOURCE Dexcom, Inc. |
|